Ftse Mib
33.629,21
-0,32%
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
NASDAQ
16.156,33
1,99%
Bitcoin
63.862,91
-0,05%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Repare Therapeutics Inc (RPTX) Repare Therapeutics Inc (RPTX) Notizie

Repare Therapeutics Inc

RPTX
3,45
0,10 (2,99%)
04 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
30/4/202413:05BWDEBIOPHARM ET REPARE THERAPEUTICS ANNONCENT LE TRAITEMENT..
26/4/202422:05BWRepare Therapeutics Appoints Steven H. Stein, M.D. to its..
05/3/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202403:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202403:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202413:05BWRepare Therapeutics to Participate in Two Upcoming Investor..
28/2/202422:09EDGAR2Form S-8 - Securities to be offered to employees in employee..
28/2/202413:15EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
28/2/202413:10EDGAR2Form 8-K - Current report
28/2/202413:05BWRepare Therapeutics Provides Business Update and Reports..
15/2/202413:05BWRepare Therapeutics Doses First Patient in Phase 1 Clinical..
15/2/202403:02EDGAR2Form SC 13G - Statement of acquisition of beneficial..
14/2/202414:54EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
12/2/202422:48EDGAR2Form 8-K - Current report
12/2/202422:05BWRepare Therapeutics to Regain Global Rights to Camonsertib
25/1/202420:29EDGAR2Form 8-K - Current report
25/1/202413:00BWRepare Therapeutics Announces Achievement of $40 Million..
12/1/202422:05EDGAR2Form 8-K - Current report
08/1/202413:00BWRepare Therapeutics Provides Corporate Update and Highlights..
04/1/202422:05BWRepare Therapeutics and Debiopharm Partner to Explore the..
29/12/202322:05BWRepare Therapeutics Insiders Establish Automatic Securities..
12/12/202322:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/11/202313:20EDGAR2Form 8-K - Current report
15/11/202313:00BWRepare Therapeutics Unveils Two Programs Expected to Enter..
09/11/202313:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202313:05EDGAR2Form 8-K - Current report
09/11/202313:00BWRepare Therapeutics Provides Business Update and Reports..
07/11/202313:00BWRepare Therapeutics to Host Investor and Analyst Conference..
06/11/202313:00BWRepare Therapeutics to Participate in Two Upcoming Investor..
13/10/202323:15EDGAR2Form 8-K - Current report
13/10/202315:47EDGAR2Form 8-K - Current report
13/10/202315:40BWRepare Therapeutics Announces Positive Initial Data from..
06/10/202313:56EDGAR2Form 8-K - Current report
03/10/202313:00BWRepare Therapeutics to Host Conference Call and Webcast to..
19/9/202313:00BWRepare Therapeutics to Present Preliminary Phase 1 MYTHIC..
06/9/202313:00BWRepare Therapeutics to Participate at the Morgan Stanley..
09/8/202322:12EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/8/202322:09EDGAR2Form 8-K - Current report
09/8/202322:05BWRepare Therapeutics Provides Business Update and Reports..
08/6/202313:00BWRepare Therapeutics to Participate at the Goldman Sachs 44th..
07/6/202322:05BWRepare Therapeutics Reports Proof of Concept for Lunresertib..
06/6/202313:00BWRepare Therapeutics Announces Publication in Nature Medicine..
02/6/202313:00BWRepare Therapeutics to Host Conference Call and Webcast to..
22/5/202313:00BWRepare Reports Inducement Grant Under Nasdaq Listing Rule..
09/5/202322:05BWRepare Therapeutics Provides Business Update and Reports..
Apertura: 3,48 Min: 3,445 Max: 3,74
Chiusura: 3,35

La tua Cronologia

NASDAQ
RPTX
Repare Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network